Analytical Data
-
基因名
dLL3
- Application
-
别名
dLL3；Delta-like Protein 3
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q9NYJ7
-
表达区间
27-492aa
-
氨基酸序列
AGVFELQIHSFGPGPGPGAPRSPCSARLPCRLFFRVCLKPGLSEEAAESP CALGAALSARGPVYTEQPGAPAPDLPLPDGLLQVPFRDAWPGTFSFIIET WREELGDQIGGPAWSLLARVAGRRRLAAGGPWARDIQRAGAWELRFSYRA RCEPPAVGTACTRLCRPRSAPSRCGPGLRPCAPLEDECEAPLVCRAGCSP EHGFCEQPGECRCLEGWTGPLCTVPVSTSSCLSPRGPSSATTGCLVPGPG PCDGNPCANGGSCSETPRSFECTCPRGFYGLRCEVSGVTCADGPCFNGGL CVGGADPDSAYICHCPPGFQGSNCEKRVDRCSLQPCRNGGLCLDLGHALR CRCRAGFAGPRCEHDLDDCAGRACANGGTCVEGGGAHRCSCALGFGGRDC RERADPCAARPCAHGGRCYAHFSGLVCACAPGYMGARCEFPVHPDGASAL PAAPPGLRPGDPQRYL
-
分子量
51 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
DLL3 (Delta-like 3) is a member of the Notch ligand family and plays a crucial role in the regulation of cell differentiation, proliferation, and development, particularly in the nervous system. Its expression is notably upregulated in various tumor types, especially neuroendocrine tumors, making it a potential target for therapeutic strategies. Research has increasingly focused on the use of DLL3 as a biomarker for tumor diagnosis and treatment, especially in small cell lung cancer (SCLC). The development of DLL3-targeted therapies, such as antibody-drug conjugates, aims to exploit its overexpression in tumors to deliver cytotoxic agents selectively to cancer cells. Recombinant DLL3 protein has been produced for various studies to understand its structure-function relationships, signaling pathways, and interaction with the Notch signaling pathway. The exploration of DLL3's role in tumor biology and its potential as a therapeutic target is a significant area of interest, as it could lead to innovative treatment options for patients with DLL3-positive tumors. Current research continues to assess the efficacy and safety of DLL3-targeted therapies in clinical trials, hoping to provide new avenues for cancer treatment and improve patient outcomes.
